Literature DB >> 15024592

[Levosimendan-long-term inodilation in an infant with myocardial infarction].

Y C Luther1, I Schulze-Neick, B Stiller, P Ewert, M Redlin, B Nasseri, E G Mühler, R Hetzer, P E Lange.   

Abstract

An infant with myocardial infarction due to congenital stenosis of the left coronary artery with consecutive left ventricular dysfunction and mitral regurgitation developed refractory pulmonary hypertension (PHT) and recurrent PHT crises. Catecholamines to support cardiac function, or pulmonary vasodilators like inhaled nitric oxide showed no effect. Treatment with Levosimendan (Simdax), a new inodilator, combining both inotropic and pulmonary vasodilating effects, improved left ventricular dysfunction, increased cardiac index, decreased pulmonary vascular resistance and reduced frequency and extent of the PHT crises. This case may suggest the use of Levosimendan as a long-term inotropic agent and pulmonary vasodilator in children with depressed cardiac function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024592     DOI: 10.1007/s00392-004-0053-9

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  3 in total

Review 1.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

2.  Levosimendan in pulmonary hypertension and right heart failure.

Authors:  Mona Sahlholdt Hansen; Asger Andersen; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2018-07-06       Impact factor: 3.017

3.  Myocardial Infarction in Neonates: A Diagnostic and Therapeutic Challenge.

Authors:  Manuel Rodríguez Martínez; Eladio Ruiz González; Anna Parra-Llorca; Máximo Vento Torres; Marta Aguar Carrascosa
Journal:  Case Rep Pediatr       Date:  2019-10-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.